Immunotherapy combined with VEGF inhibitors for kidney cancer

In this video interview, Dr Shilpa Gupta, assistant professor, Haematology, Oncology and Transplantation Division, University of Minnesota, USA, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer. Since kidney cancer is a VEGF-driven disease, it makes sense to combine VEGF inhibitors, such as sunitinib or axitinib, with immunotherapy drugs, such as nivolumab or […] [...]

read more

Neoadjuvant and adjuvant therapy for kidney cancer

A comprehensive review of neoadjuvant therapy and adjuvant therapy for kidney cancer was presented at the American Urology Association conference in Boston, America, last week. In kidney cancer, neoadjuvant (before surgery) and adjuvant (after surgery) therapies have achieved a variety of outcomes. Neoadjuvant therapy has been used to try and shrink kidney tumours and facilitate the […] [...]

read more

Barriers to biopsy of small renal masses

A recent survey of Canadian Urologists assessed the use of renal tumour biopsy in the management of small renal masses and identified barriers to a more widespread use of renal tumour biopsy. Renal tumour biopsy has been demonstrated to be a safe procedure, and without the perceived risk of spreading the cancer cells throughout the […] [...]

read more

International Clinical Trials Day 20th May 2017

This coming Saturday 20th May is International Clinical Trials Day, which has been held on 20th May each year since 2005 to commemorate the day James Lind started the first clinical trial. The National Institute for Health Research (NIHR) are launching a campaign called ‘I Am Research’ to raise awareness of the benefits of research and […] [...]

read more

Alternative sunitinib dosing schedule for the treatment of kidney cancer improves adverse events

Recently, the results of several studies have demonstrated that a 2 weeks on treatment, 1 week off treatment (2/1) dosing schedule for sunitinib improves adverse events, without reducing efficacy, in patients with metastatic renal cell carcinoma (RCC). Read a review article here and an article presenting real world evidence with a 2/1 dosing schedule for sunitinib […] [...]

read more

Management of renal medullary carcinoma

Renal medullary carcinoma is a very rare subtype of renal cell carcinoma. This is a very devastating tumour, and it affects mostly patients of African descent, and patients with the sickle-cell trait. These patients in general have a survival of about one year from diagnosis, which is very devastating in this typically young patient population. […] [...]

read more
Showing 1 to 6 of 157 results
  TOP